The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American ...

Lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for more North Dakotans.

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

High Return on Equity: With a three-year average ROE of 101% and an ROE of 123% in the last year, the company has ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

With the close of 2024 and the launch of a new year, we can take a moment to look back at what was another eventful, ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...